1. Home
  2. BANR vs NKTR Comparison

BANR vs NKTR Comparison

Compare BANR & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banner Corporation

BANR

Banner Corporation

HOLD

Current Price

$70.29

Market Cap

2.3B

Sector

Finance

ML Signal

HOLD

Logo Nektar Therapeutics

NKTR

Nektar Therapeutics

HOLD

Current Price

$70.73

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANR
NKTR
Founded
1890
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.2B
IPO Year
2015
1996

Fundamental Metrics

Financial Performance
Metric
BANR
NKTR
Price
$70.29
$70.73
Analyst Decision
Hold
Strong Buy
Analyst Count
4
7
Target Price
$70.00
$146.67
AVG Volume (30 Days)
424.7K
1.1M
Earning Date
04-22-2026
05-07-2026
Dividend Yield
3.14%
N/A
EPS Growth
15.57
N/A
EPS
1.60
N/A
Revenue
N/A
$307,711,000.00
Revenue This Year
$0.73
N/A
Revenue Next Year
$5.69
N/A
P/E Ratio
$43.03
N/A
Revenue Growth
N/A
86.00
52 Week Low
$57.05
$21.02
52 Week High
$72.65
$109.00

Technical Indicators

Market Signals
Indicator
BANR
NKTR
Relative Strength Index (RSI) 57.62 54.99
Support Level $62.97 $64.30
Resistance Level $72.65 $76.78
Average True Range (ATR) 1.57 3.47
MACD -0.00 0.04
Stochastic Oscillator 60.71 47.61

Price Performance

Historical Comparison
BANR
NKTR

About BANR Banner Corporation

Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho, and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Share on Social Networks: